Tijeras-Raballand A - Search Results

1

Unraveling galectin-1 as a novel therapeutic target for cancer.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S. Astorgues-Xerri L, et al. Cancer Treat Rev. 2014 Mar;40(2):307-19. doi: 10.1016/j.ctrv.2013.07.007. Epub 2013 Aug 1. Cancer Treat Rev. 2014. PMID: 23953240 Review.

2

Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue.

Albert S, Hourseau M, Halimi C, Serova M, Descatoire V, Barry B, Couvelard A, Riveiro ME, Tijeras-Raballand A, de Gramont A, Raymond E, Faivre S. Albert S, et al. Oral Oncol. 2012 Dec;48(12):1263-71. doi: 10.1016/j.oraloncology.2012.06.010. Epub 2012 Jul 7. Oral Oncol. 2012. PMID: 22776129

3

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.

Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S. Tijeras-Raballand A, et al. Target Oncol. 2012 Sep;7(3):173-81. doi: 10.1007/s11523-012-0229-6. Epub 2012 Aug 25. Target Oncol. 2012. PMID: 22923165 Review.

4

Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.

Neuzillet C, Hammel P, Tijeras-Raballand A, Couvelard A, Raymond E. Neuzillet C, et al. Cancer Metastasis Rev. 2013 Jun;32(1-2):147-62. doi: 10.1007/s10555-012-9396-2. Cancer Metastasis Rev. 2013. PMID: 23085856 Review.

5

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.

Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E. Serova M, et al. Cancer Chemother Pharmacol. 2013 May;71(5):1297-307. doi: 10.1007/s00280-013-2129-6. Epub 2013 Mar 12. Cancer Chemother Pharmacol. 2013. PMID: 23479136

6

Stromal expression of SPARC in pancreatic adenocarcinoma.

Neuzillet C, Tijeras-Raballand A, Cros J, Faivre S, Hammel P, Raymond E. Neuzillet C, et al. Cancer Metastasis Rev. 2013 Dec;32(3-4):585-602. doi: 10.1007/s10555-013-9439-3. Cancer Metastasis Rev. 2013. PMID: 23690170 Review.

7

MEK in cancer and cancer therapy.

Neuzillet C, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. Neuzillet C, et al. Pharmacol Ther. 2014 Feb;141(2):160-71. doi: 10.1016/j.pharmthera.2013.10.001. Epub 2013 Oct 9. Pharmacol Ther. 2014. PMID: 24121058 Review.

8

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.

Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, Faivre S, Raymond E. Neuzillet C, et al. Oncotarget. 2014 Jan 15;5(1):78-94. doi: 10.18632/oncotarget.1569. Oncotarget. 2014. PMID: 24393789 Free PMC article. Review.

9

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, Vidaud M, de Gramont A, Martinet M, Cvitkovic E, Faivre S, Raymond E. Astorgues-Xerri L, et al. Eur J Cancer. 2014 Sep;50(14):2463-77. doi: 10.1016/j.ejca.2014.06.015. Epub 2014 Jul 16. Eur J Cancer. 2014. PMID: 25042151

10

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.

Dos Santos C, Tijeras-Raballand A, Serova M, Sebbagh S, Slimane K, Faivre S, de Gramont A, Raymond E. Dos Santos C, et al. Br J Cancer. 2015 Jan 6;112(1):86-94. doi: 10.1038/bjc.2014.578. Epub 2014 Nov 25. Br J Cancer. 2015. PMID: 25422908 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30 results

Search Page

Filters